AstraZeneca (AZN) Enters Brodalumab Licensing Agreement with Valeant (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
September 2, 2015 10:23 AM EDTBMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
Valeant picks up AstraZeneca psoriasis drug after Amgen exit
September 1, 2015 2:31 AM EDT(Reuters) - Canada's Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) is buying rights to AstraZeneca Plc's (NYSE: AZN) late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc (NASDAQ: AMGN) in... More
FDA Issues Warning on DPP-4 Inhibitors in T2D (MRK) (LLY)
August 28, 2015 12:36 PM EDTThe U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. We have added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right... More
